Search

Your search keyword '"Coveler, Andrew"' showing total 200 results
Start Over Author "Coveler, Andrew" Database Unpaywall
200 results on '"Coveler, Andrew"'

1. Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER).

Author

Strickler, John H, primary, Cercek, Andrea, additional, Siena, Salvatore, additional, Andre, Thierry, additional, Ng, Kimmie, additional, Van Cutsem, Eric, additional, Wu, Christina, additional, Paulson, Andrew Scott, additional, Hubbard, Joleen M., additional, Coveler, Andrew L., additional, Fountzilas, Christos, additional, Kardosh, Adel, additional, Kasi, Pashtoon Murtaza, additional, Lenz, Heinz-Josef, additional, Ciombor, Kristen Keon, additional, Elez, Elena, additional, Bajor, David L, additional, Nayeri, Mina, additional, Feng, Wentao, additional, and Bekaii-Saab, Tanios S., additional

Published
2024
Full Text
View/download PDF

2. The power of personas: Exploring an innovative model for understanding stakeholder perspectives in an oncology learning health network

Author

Cooper, Dylan J., primary, Karten, Jessie, additional, Hoffe, Sarah E., additional, King, Daniel A., additional, Weiss, Matthew, additional, DePeralta, Danielle K., additional, Coveler, Andrew L., additional, Hingorani, Sunil R., additional, Shefter, Tracey, additional, Meguid, Cheryl, additional, Roberts, Hannah, additional, Hong, Theodore S., additional, Narang, Amol, additional, Hacker‐Prietz, Amy, additional, Fisher, George A., additional, Sandler, Jay, additional, Singer, Laurie, additional, Korah, Bobby, additional, Hoos, William, additional, Stricker, Carrie T., additional, and Herman, Joseph M., additional

Published
2024
Full Text
View/download PDF

3. A multicenter phase Ia study of AbGn-107, a novel antibody–drug conjugate, in patients with advanced gastrointestinal cancer

Author

Ko, Andrew H., primary, Coveler, Andrew L., additional, Schlechter, Benjamin L., additional, Bekaii-Saab, Tanios, additional, Wolpin, Brian M., additional, Clark, Jeffrey W., additional, Bockorny, Bruno, additional, Bai, Li-Yuan, additional, Lin, Yu-Chin, additional, Chiang, Evelyn, additional, Langecker, Peter, additional, and Lin, Shih-Yao, additional

Published
2024
Full Text
View/download PDF

4. Supplementary Figure S9 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

5. Supplementary Figure S14 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

6. Supplementary Table S8 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

7. Supplementary Figure S11 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

8. Supplementary Figure S11 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

9. Data from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

10. Supplementary Table S8 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

11. Supplementary Table S1 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

12. Supplementary Table S4 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

13. Supplementary Figure S12 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

14. Supplementary Figure S3 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

15. Supplementary Figure S8 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

16. Supplementary Table S6 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

17. Supplementary Figure S7 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

18. Supplementary Figure S13 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

19. Supplementary Figure S2 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

20. Supplementary Table S3 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

21. Supplementary Table S9 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

22. Supplementary Figure S17 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

23. Supplementary Table S9 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

24. Supplementary Figure S7 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

25. Supplementary Figure S12 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

26. Supplementary Figure S10 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

27. Supplementary Table S10 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

28. Supplementary Figure S4 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

29. Supplementary Figure S14 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

30. Supplementary Figure S15 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

31. Supplementary Table S3 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

32. Supplementary Figure S5 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

33. Supplementary Figure S3 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

34. Supplementary Table S5 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

35. Supplementary Figure S9 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

36. Supplementary Figure S4 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

37. Supplementary Figure S10 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

38. Supplementary Figure S6 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

39. Supplementary Figure S6 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

40. Supplementary Table S7 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

41. Supplementary Table S7 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

42. Supplementary Figure S18 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

43. Supplementary Figure S15 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

44. Supplementary Figure S16 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

45. Supplementary Figure S16 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

46. Supplementary Figure S13 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

47. Supplementary Table S10 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

48. Supplementary Figure S1 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

49. Supplementary Figure S8 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

50. Supplementary Table S2 from Phase I Study of Elraglusib (9-ING-41), a Glycogen Synthase Kinase-3β Inhibitor, as Monotherapy or Combined with Chemotherapy in Patients with Advanced Malignancies

Author

Carneiro, Benedito A., primary, Cavalcante, Ludimila, primary, Mahalingam, Devalingam, primary, Saeed, Anwaar, primary, Safran, Howard, primary, Ma, Wen Wee, primary, Coveler, Andrew L., primary, Powell, Steven, primary, Bastos, Bruno, primary, Davis, Elizabeth, primary, Sahai, Vaibhav, primary, Mikrut, William, primary, Longstreth, James, primary, Smith, Sheri, primary, Weisskittel, Taylor, primary, Li, Hu, primary, Borden, Brittany A., primary, Harvey, R. Donald, primary, Sahebjam, Solmaz, primary, Cervantes, Andrés, primary, Koukol, Austin, primary, Mazar, Andrew P., primary, Steeghs, Neeltje, primary, Kurzrock, Razelle, primary, Giles, Francis J., primary, and Munster, Pamela, primary

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results